139 related articles for article (PubMed ID: 28245480)
1. Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer.
Porcaro AB; de Luyk N; Corsi P; Sebben M; Tafuri A; Mattevi D; Processali T; Cerruto MA; Brunelli M; Zecchini Antoniolli S; Siracusano S; Artibani W
Urol Int; 2017; 99(2):207-214. PubMed ID: 28245480
[TBL] [Abstract][Full Text] [Related]
2. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Mattevi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli MA; Migliorini F; Siracusano S; Artibani W
Urol Int; 2017; 99(4):392-399. PubMed ID: 28486228
[TBL] [Abstract][Full Text] [Related]
3. Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer.
Porcaro AB; de Luyk N; Corsi P; Sebben M; Tafuri A; Tamanini I; Processali T; Cerruto MA; Migliorini F; Brunelli M; Siracusano S; Artibani W
Tumori; 2017 May; 103(3):299-306. PubMed ID: 27716882
[TBL] [Abstract][Full Text] [Related]
4. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
5. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
[TBL] [Abstract][Full Text] [Related]
6. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.
Porcaro AB; Corsi P; Inverardi D; Sebben M; Tafuri A; Processali T; Mattevi D; De Marchi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli M; Siracusano S; Artibani W
Tumori; 2018 Aug; 104(4):307-311. PubMed ID: 29714659
[TBL] [Abstract][Full Text] [Related]
8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
9. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
Wilczak W; Wittmer C; Clauditz T; Minner S; Steurer S; Büscheck F; Krech T; Lennartz M; Harms L; Leleu D; Ahrens M; Ingwerth S; Günther CT; Koop C; Simon R; Jacobsen F; Tsourlakis MC; Chirico V; Höflmayer D; Vettorazzi E; Haese A; Steuber T; Salomon G; Michl U; Budäus L; Tilki D; Thederan I; Fraune C; Göbel C; Henrich MC; Juhnke M; Möller K; Bawahab AA; Uhlig R; Adam M; Weidemann S; Beyer B; Huland H; Graefen M; Sauter G; Schlomm T
Eur Urol; 2018 Sep; 74(3):376-386. PubMed ID: 29908878
[TBL] [Abstract][Full Text] [Related]
10. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
[TBL] [Abstract][Full Text] [Related]
12. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
13. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
16. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
[TBL] [Abstract][Full Text] [Related]
17. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
[TBL] [Abstract][Full Text] [Related]
18. Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
Draulans C; Everaerts W; Isebaert S; Van Bruwaene S; Gevaert T; Oyen R; Joniau S; Lerut E; De Wever L; Laenen A; Weynand B; Defraene G; Vanhoutte E; De Meerleer G; Haustermans K
J Urol; 2020 Apr; 203(4):713-718. PubMed ID: 31718396
[TBL] [Abstract][Full Text] [Related]
19. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
20. Predicting pelvic lymph node involvement in current-era prostate cancer.
Rahman S; Cosmatos H; Dave G; Williams S; Tome M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
